Erste Phase-I-Untersuchung von Echinacea-Polisaccharid (EPO VIIa/EPS) bei i.vi Applikation

Author(s): Worku, F., Linde, K., Flesche, C., Eife, R., Wagner, H.

Journal/Book: Erfahrungsheilkunde. 1993; 6: 318-323.

Abstract: Objectives: To assess the immunostimulating effects, the compatibility and to find out the optimal dose and time of administration of an i.v. application of a polysaccharide fraction (EPO Vila) isolated from tissue cultures of Echinacea purpurea.Design: 6 randomized, double-blind, placebo-controlled trials, partially crossover.Subjects: 32 healthy, male volunteers between 21 and 37 years.Main outcome measures: Leucocytes (total and differentiated), phagocytosis of polymorphonuclear neutrophile granulocytes, TNF-alpha, interferon-alpha, activity of NK-cells and lymphocyte subpopulations.Results: Injections of I mg and 5 mg EPO VIIa caused an increase of the number of leucocytes (90-150% and 50-90% respectively) segmented granulocytes and TNF-alpha (from < 15 pg/ml to < 15-32 pg/ml and 32-115 pg/ml respectively). In two volunteers 5 mg caused short-time influenza-like symptoms and limb pain.Conclusion: 1 mg EPO VIIa caused a distinct increase of unspecific immunoparameters. The relevance for therapeutics should be tested in clinical studies.

Keyword(s): Echinacea-Polisaccharid

Zurück | Weiter